AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Veteran marketing executive Amy Atkinson has acquired Muskegon Heights-based RCP Marketing, where she has served as president ...

"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class ...

I-Mab, a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will ...

Synechron, Inc., a leading global digital transformation consulting firm, announced today that it has acquired Cloobees, an award winning, top-tier Salesforce implementation partner. Cloobees will add ...

WHAT TO WATCH --VACCINES: Investors' concerns linger over sales expectations for the company's respiratory syncytial virus vaccine Arexvy and its best-selling shingles vaccine Shingrix for the ...

The 2023 approval of the world’s first RSV vaccines in the US and Europe, GSK’s AREXVY and Pfizer’s ABRYSVO, was a significant milestone in addressing the grave unmet medical needs associated with RSV ...

The 2023 approval of the world's first RSV vaccines in the US and Europe, GSK’s AREXVY and Pfizer’s ABRYSVO, was a significant milestone in addressing the grave unmet medical needs associated ...

We are pleased that AREXVY remains among the vaccines being offered this season, and that older Ontarians will continue to benefit from the protection offered by RSV vaccines." "As a company invested ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...

AS artificial intelligence (AI) becomes a cornerstone in modern marketing, brands are discovering its power to deliver personalized experiences and streamline operations. My recent talk at Adamson ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...